PCSK9 inhibitors, monoclonal antibodies that bind to free PCSK9, have potent effect on LDL-C reduction, and are recommended to use in patients with high CVD risk or familial hypercholesterolemia [34]. The gene discussed is PCSK9; the disease is familial hypercholesterolemia.